Q2FY25: Cipla reports 15.2% rise in net profit to Rs 1303 crore; Slow growth reported in acute category

Pharma major Cipla on Tuesday announced its unaudited consolidated financial results for the quarter ended September 30th, 2024.

The company reported an 15.2 percent year-on-year rise in its consolidated net profit for the fiscal’s second quarter ended September (Q2FY25) to Rs. 1,303.53 crore.

The company had reported a profit of Rs. 1,177.64 crore in the year-ago period. Moreover, the consolidated net profit was up 10.6 percent.

Also Read Bajaj Finserv Q2 Results: Profit rises by 8.2% to Rs 2,086.97 crore, revenue up 29.5% YoY Nestle Q2 Results: Maggi-maker posts marginal decline in profit at Rs 899.49 crore but beats estimates, revenue up 1.3% YoY L&T Tech posts Q2 profit at Rs 319.60 crore, revenue rises by 7.8% YoY; FY25 guidance maintained IREDA’s net profit surges 36 per cent on-year in Q2FY25

According to the company’s statement, the Cipla’s consolidated revenue from operations stood at Rs. 7,051.02 crores during the quarter ended September from Rs.6,678.15 crore in Q2FY24, a year-on-year jump of nearly 10.5 percent.

One India Business grew at 5 percent YoY. Branded Prescription business continued to outpace the market in key Chronic therapies. CHL delivered strong growth at 21% YoY. The business however, witnessed a historically slow seasonal growth in Acute category impacting both Branded Prescription and Trade Generics business, the company stated.

Meanwhile, the North America business delivered quarterly revenue of $ 237 Mn up by 4% YoY supported by traction in differentiated portfolio.

In the One Africa business, the North Africa business which was a part of Emerging markets and Europe is now merged with SAGA region which is renamed as One Africa. Momentum continues with overall revenue growth at 22 percent.

Emerging Markets and Europe posted a robust revenue growth of 18% in USD terms. Additionally, R&D investments stood at Rs. 385 Crore or 5.5 percent of sales, higher by 2 percent YoY driven by product filings and developmental efforts.

The company has Net cash position of INR 7,950 Cr and debt primarily includes lease liabilities and working capital requirements.

Also ReadQ2 Result 2024 Live Updates: Maruti Suzuki India, Adani Enterprises, Cipla, Marico, V-Mart, others releasing Q2 report today

“I am pleased to share that we continue to make considerable progress across our focused markets.

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth